Korean LG Life Sciences Plans BLA Submission For Biosimilar Somatropin To U.S. FDA

SEOUL - South Korea's LG Life Sciences completed its Phase III clinical trial of its slow-release recombinant human growth hormone somatropin weekly injection for treating adults with growth hormone deficiency, and is getting its biologics license application ready for U.S. FDA for the new formulation